311 related articles for article (PubMed ID: 12888590)
1. Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact.
Baldanti F; Gerna G
J Antimicrob Chemother; 2003 Sep; 52(3):324-30. PubMed ID: 12888590
[TBL] [Abstract][Full Text] [Related]
2. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay.
Eckle T; Jahn G; Hamprecht K
J Clin Virol; 2004 May; 30(1):50-6. PubMed ID: 15072754
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.
Baldanti F; Lurain N; Gerna G
Hum Immunol; 2004 May; 65(5):403-9. PubMed ID: 15172438
[TBL] [Abstract][Full Text] [Related]
5. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients.
Lurain NS; Bhorade SM; Pursell KJ; Avery RK; Yeldandi VV; Isada CM; Robert ES; Kohn DJ; Arens MQ; Garrity ER; Taege AJ; Mullen MG; Todd KM; Bremer JW; Yen-Lieberman B
J Infect Dis; 2002 Sep; 186(6):760-8. PubMed ID: 12198609
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus resistance testing: pitfalls and problems for the clinician.
Drew WL
Clin Infect Dis; 2010 Mar; 50(5):733-6. PubMed ID: 20100090
[TBL] [Abstract][Full Text] [Related]
7. Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR.
Schnepf N; Boiteau N; Petit F; Alain S; Sanson-Le Pors MJ; Mazeron MC
Antiviral Res; 2009 Jan; 81(1):64-7. PubMed ID: 18992772
[TBL] [Abstract][Full Text] [Related]
8. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
Campos AB; Ribeiro J; Boutolleau D; Sousa H
Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
[TBL] [Abstract][Full Text] [Related]
9. Antiviral strategies to combat cytomegalovirus infections in transplant recipients.
Lischka P; Zimmermann H
Curr Opin Pharmacol; 2008 Oct; 8(5):541-8. PubMed ID: 18662804
[TBL] [Abstract][Full Text] [Related]
10. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child.
Iwasenko JM; Scott GM; Ziegler JB; Rawlinson WD
J Clin Virol; 2007 Oct; 40(2):152-5. PubMed ID: 17698411
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in human cytomegalovirus diagnosis.
Halwachs-Baumann G
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):427-39. PubMed ID: 17547507
[TBL] [Abstract][Full Text] [Related]
12. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
[TBL] [Abstract][Full Text] [Related]
13. Emergence of multiple drug-resistant human cytomegalovirus variants in 2 patients with human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy.
Baldanti F; Paolucci S; Parisi A; Meroni L; Gerna G
Clin Infect Dis; 2002 Apr; 34(8):1146-9. PubMed ID: 11915006
[TBL] [Abstract][Full Text] [Related]
14. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection.
Alain S; Hantz S; Scieux C; Karras A; Mazeron MC; Szelag JC; Imbert BM; Fillet AM; Gouarin S; Mengelle C; De Wilde A; Cogne N; Champier G; Rogez S; Legendre C; Denis F
J Med Virol; 2004 Aug; 73(4):566-73. PubMed ID: 15221901
[TBL] [Abstract][Full Text] [Related]
15. Human cytomegalovirus DNA replication: antiviral targets and drugs.
Mercorelli B; Sinigalia E; Loregian A; Palù G
Rev Med Virol; 2008; 18(3):177-210. PubMed ID: 18027349
[TBL] [Abstract][Full Text] [Related]
16. Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
Boutolleau D; Canestri A; Burrel S; Wirden M; Seang S; Clavel-Osorio C; Marcelin AG; Katlama C; Agut H
J Clin Virol; 2012 Jun; 54(2):194-6. PubMed ID: 22398036
[TBL] [Abstract][Full Text] [Related]
17. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain.
Hamprecht K; Eckle T; Prix L; Faul C; Einsele H; Jahn G
J Infect Dis; 2003 Jan; 187(1):139-43. PubMed ID: 12508158
[TBL] [Abstract][Full Text] [Related]
18. Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.
Göhring K; Mikeler E; Jahn G; Rohde F; Hamprecht K
Antivir Ther; 2008; 13(3):461-6. PubMed ID: 18572760
[TBL] [Abstract][Full Text] [Related]
19. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes.
Chevillotte M; von Einem J; Meier BM; Lin FM; Kestler HA; Mertens T
Antiviral Res; 2010 Feb; 85(2):318-27. PubMed ID: 19853628
[TBL] [Abstract][Full Text] [Related]
20. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
